Benchmark raised the firm’s price target on Integer to $130 from $105 and keeps a Buy rating on the shares. Integer, which has benefited this year from momentum in the medical device and contract manufacturing sectors, including recent buyouts, is set to report financial results for their fiscal Q1 on April 25 and quarterly comparisons “look very strong to start off the 2024 year,” the analyst tells investors in a preview note. The firm estimates revenue growth of 9.4% and EPS of $1.16 on a non-GAAP basis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITGR:
- Integer initiated with a Buy at CL King
- A New Cause for Concern: Integer Holdings Adds a New Debt & Financing Risk
- Integer management to meet with Piper Sandler
- Integer Holdings Unveils Updated Earnings Presentation for 2023
- Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2023
